肝炎平对D－氨基半乳精所致肝损害保护作用的酶组织化学研究

本实验采用Ｄ－氨基半乳糖（Ｄ－ＧａｌＮ）诱导的大鼠急性肝损伤模型,观察大鼠肝脏组织化学的变化,探讨肝炎平对急性肝损伤的保护作用。实验分为四组,即正常对照组、模型组、肝炎平及肝得健保护组。结果表明：肝炎平对肝细胞膜系统有一定的保护作用。肝炎平组和肝得健组ＳＤＨ、ＣＣＯ及ＣｈＥ活性明显高于模型组,且与正常对照组相近。本实验模型组ＡＣＰ的活性明显高于正常组,而肝炎平组ＡＣＰ的活性明显低于模型组,与正常对照组无显著性差异。提示：肝炎平可显著改善因Ｄ－氨基半乳糖所致肝损害的作用。且其对肝细胞的保护作用与肝得健一致。     

肺血管EDNO及其合酶在大鼠低氧性肺动脉高压形成中的作用

本研究观察了低氧对大鼠肺组织和血管内皮一氧化氮合酶（ＮＯＳ）活性及内皮衍生一氧化氮（ＥＤＮＯ）依赖性舒张反应的影响,以及ＮＯＳ抑制剂（Ｌ－ＮＡＭＥ）对常氧和低氧大鼠肺组织和血管内皮ＮＯＳ活性及颈、肺动脉血压（ＣＡＰｓ、ｍＰＡＰ）的作用。结果表明常氧大鼠肺泡内无肌性血管内皮未见ＮＯＳ活性,其肺血管床对ＥＤＮＯ依赖性舒血管物质ＢＫ没有反应,注射Ｌ－ＮＡＭＥ后大鼠ｍＰＡＰ略有降低,ＣＡＰｓ有所升高。低氧大鼠肺泡内无肌性血管内皮显示ＮＯＳ活性,对ＢＫ的ＥＤＮＯ依赖性舒张反应呈剂量依赖性增大,注射Ｌ－ＮＡＭＥ使低氧大鼠ｍＰＡＰ显著降低（Ｐ＜０．０１）,ＣＡＰｓ显著升高（Ｐ＜０．０５）。提示肺血管ＥＤＮＯ及其合酶在维持正常成年大鼠肺循环低压低阻中的生理作用值得进一步探讨;低氧引起肺血管内皮ｅｃＮＯＳ活性增加和ＥＤＮＯ生成增多可能起到限制肺动脉压过度升高的调制作用,也可能对肺血管内皮产生毒性作用,反而促进肺动脉高压的发生和发展。     

青心酮对妊娠高血压综合征胎盘血管内皮和平滑肌细胞内一氧化氮合酶的影响

本文对正常孕妇、妊娠高血压综合征（ＰＩＨ）患者和经青心酮（ＤＨＡＰ）治疗的ＰＩＨ患者等共２４例,应用组织化学分析方法观察胎盘血管内皮细胞（ＶＥＣ）和平滑肌细胞（ＶＳＭＣ）内一氧化氮合酶（ＮＯＳ）活性的变化。结果表明：正常孕妇胎盘ＶＥＣ和ＶＳＭＣ内ＮＯＳ活性较高;ＰＩＨ胎盘ＶＥＣ和ＶＳＭＣ内ＮＯＳ活性明显减弱,并伴有组织和细胞的形态学损伤;经ＤＨＡＰ治疗后的ＰＩＨ胎盘ＶＥＣ和ＶＳＭＣ细胞ＮＯＳ活性较未经ＤＨＡＰ治疗者明显增加,其组织和细胞损伤也减轻。本研究结果提示胎盘内ＶＥＣ和ＶＳＭＣ细胞的ＮＯＳ减少可能与ＰＩＨ的发生和／或发展有关,青心酮治疗ＰＩＨ的作用可能与ＤＨＡＰ促进胎盘ＶＥＣ和ＶＳＭＣ内一氧化氮（ＮＯ）合成有关。     

一氧化氮在胃肠运动及胃肠病理中的作用

近几年来的研究表明,ＮＡＮＣ神经元内存在ＮＯ合成酶系,刺激神经后有ＮＯ的释放,外源性ＮＯ可产生同电刺激ＮＡＮＣ神经相似的反应,同时使用ＮＯ合成抑制剂可阻断电刺激ＮＡＮＣ神经后的反应,所有这些实验资料一致说明ＮＯ是ＮＡＮＣ神经的一种抑制性神经递质。ＮＯ在人和哺乳动物的消化道内广泛分布,对胃肠道平滑肌的正常运动起着调节作用,并与胃肠疾病,肝硬化的形成有关,因而可能具有重要的临床意义。     

一氧化氮合酶的研究进展

一氧化氮是由Ｌ－精氨酸和氧分子在一氧化氮合酶及其辅因子ＮＡＤＰＨ、ＦＡＤ、ＦＭＮ、ＣａＭ和ＢＨ４催化作用生成的;ＮＯＳ分为原生型和诱生型ＮＯＳ,原生型ＮＯＳ活性依赖于胞浆内Ｃａ＾２＋水平,诱生型ＮＯＳ是Ｃａ＾２＋／ＣａＭ非依赖性酶,其活性开关是胞内ｎＮＯＳ ｍＲＮＡ水平,ＮＯＳ可在多个水平被调节;ＮＯＳ可能在心血管疾病的发病中起重要作用。     

强啡肽对脊髓原生型与诱生型一氧化氮合成酶活性、分布和基因表达的影响及机制

蛛网膜下腔注射（ｉ．ｔ．）强啡肽Ａ１－１７（Ｄｙｎ）引起剂量依赖性后肢和尾部瘫痪及甩尾甩足抑制。脊髓背角（侧）ＮＭＤＡ受体和ＮＯＳ／ＮＯ功能活性下降可能与Ｄｙｎ镇痛作用有关,脊髓腹角（侧）ＮＭＤＡ受体－Ｃａ２＋－ＮＯＳ／ＮＯ通路过度激活及ｃ－ｆｏｓ高表达可能与Ｄｙｎ致脊髓损伤（ＳＣＩ）作用有关。在Ｄｙｎ致ＳＣＩ机制中,过量ＮＯ（细胞水平）具有神经毒性作用,脑源性ＮＯＳ主要在早期,诱生型ＮＯＳ主要在后期起作用,而内皮细胞源性ＮＯＳ和适量ＮＯ（血管水平）可能具有保护作用。在原代培养脊髓神经元中,高浓度Ｄｙｎ可通过ＮＭＤＡ受体和κ受体直接引起细胞内Ｃａ２＋超负荷,低浓度Ｄｙｎ只通过κ受体抑制高钾刺激性Ｃａ２＋内流     

冬小麦不同生育时期水分亏缺胁迫对叶片保护酶系统的影响

利用盆栽试验研究了施Ｎ（底肥）与不施Ｎ条件下冬小麦不同生育时期水分有限亏缺对叶片保护酶系统的影响,结果表明,在无底肥条件下,３个生育时期水分亏缺均使保护酶系统活性有所降低,而在有底肥时酶活性多数则升高,各保护酶活性与ＭＤＡ相关分析表明,苗期ＳＯＤ活性与ＭＤＡ呈极显著负相关;拔节却是ＰＯＤ活性与ＭＤＡ呈极显著负相关;在灌浆期ＳＯＤ、ＰＯＤ、ＣＡＴ与ＭＤＡ含量均无显著相关性,但ＭＤＡ在叶片中累积至较高水平。各生育期水分处理叶片绿素含量与ＭＤＡ含量达极显著负相关。这些说明在不同生育时期,受水分亏缺和供的,保护酶系统各酶的变化有明显差异。其生理作用也有差异。     

硝酸钾缓解氯化钠胁迫蓝藻Anabaena 7120固氮的生理基础

营养液中添加适量ＫＮＯ３可在一定程度上缓解ＮａＣｌ对鱼腥藻固氮活性的抑制作用。暗处理或加光合抑制剂时,ＫＮＯ３对ＮａＣｌ胁迫的缓解作用便消失。供给外源蔗糖、提高ＣＯ２浓度、同时供给ＣＯ２和Ｎ２时,ＫＮＯ３对缓解ＮａＣｌ胁迫的作用则增高．同时供给Ｏ２和Ｈ２对ＫＮＯ３的缓解作用增高影响较小,而在厌氧（Ａｒ或Ｎ２中）或单加氧下,ＫＮＯ３的缓解效应则明显减弱或消失．     

维拉帕米对骨骼肌缺血再灌注损伤保护作用的酶组织化学研究

实验选用大鼠骨骼肌缺血再灌注模型, 观察骨骼肌缺血及再灌注后酶组织化学和超微结构的变化, 并观察维拉帕米的保护作用。结果显示： 骨骼肌缺血６ｈ 时, 骨骼肌细胞ＳＤＨ、ＣＣＯ、Ｃａ２＋ －ＡＴＰａｓｅ活性呈下降趋势, 而ＬＤＨ 活性则有所增强。再灌注１２ｈ 时, 骨骼肌细胞ＳＤＨ、ＣＣＯ、Ｃａ２＋ －ＡＴＰａｓｅ 活性进一步明显下降,同时ＬＤＨ 活性亦下降明显,而应用维拉帕米能在一定程度上保护上述酶的活性。与此同时,骨骼肌超微结构的改变与其酶活性的变化相一致。因此, 本实验提示： 骨骼肌缺血再灌注可损害其能量代谢酶的活性, 而维拉帕米则有较强的保护作用。     

一氧化氮：奥迪氏括约肌的重要信使物质

奥迪氏括约肌（ＳＯ）的非肾上腺素能非胆碱能（ＮＡＮＣ）神经元和和神经纤维与其它胃肠道一样也存在一氧化氮合酶（ＮＯＳ）。刺激ＳＯ神经后有ＮＯ释放,应用能直接释放ＮＯ的药物硝普钠所产生的效应同刺激ＳＯ的ＮＡＮＣ神经的效应十分相似。使用ＮＯＳ抑制剂可阻断刺激ＮＡＮＣ神经所引起舒张反应。提示ＮＯ是ＮＡＮＣ神经的抑制性递质之一。ＮＯ广泛分布于人和哺乳动物的ＳＯ,对其正常生理运动起抑制性调控作用。此外,ＮＯ可     

铁棍山药多糖对四氯化碳诱导的急性小鼠肝损伤的保护作用

为了研究铁棍山药(D.oppositacv.Tiegun)多糖对四氯化碳诱导的小鼠急性肝损伤的保护作用,取72只昆明小鼠随机分为对照组,四氯化碳(CCl4)模型组,阳性对照(联苯双酯)组,铁棍山药多糖低、中、高剂量组,每组12只,灌胃处理后使用CCl4制备急性肝损伤小鼠模型,观察各组形态学变化,同时测定生化指标。实验结果显示,经铁棍山药多糖处理的小鼠的肝损伤程度明显轻于模型组,铁棍山药多糖能降低小鼠血清中谷丙转氨酶(ALT)和谷草转氨酶(AST)含量,提高超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)的活性,降低丙二醛(MDA)、一氧化氮(NO)、肿瘤坏死因子-α(TNF-α)的含量。本研究结果表明,铁棍山药多糖对CCl4所诱导的小鼠肝损伤起到一定的保护作用。     

Augmenter of liver regeneration (ALR) gene therapy attenuates CCl₄-induced liver injury and fibrosis in rats

Liver fibrosis represents a process of healing and scarring in response to chronic liver injury. Augmenter of liver regeneration (ALR) has been shown to protect hepatocytes from various toxins. The aim of this study was to investigate the effects of ALR gene therapy on liver injury and fibrosis induced by CCl(4) in rats and further explore the underlying mechanisms. Human ALR expression plasmid was delivered via the tail vein. ALR gene therapy might protect the liver from CCl(4)-induced injury and fibrogenesis by attenuating the mitochondrial dysfunction, suppressing oxidative stress, and inhibiting activation of HSCs. This report demonstrated that ALR gene therapy protected against the ATP loss, increased the activity of ATPase, decreased intrahepatic reactive oxygen species level, and down-regulated transforming growth factor-β1, platelet-derived growth factor-BB, and α-smooth muscle actin expression. Following gene transfer liver function tests were significantly improved. In brief, ALR gene therapy might be an effective therapeutic reagent for liver fibrosis with potential clinical applications.     

The Protective Effect of ENA Actimineral Resource A on CCl4-Induced Liver Injury in Rats

ENA Actimineral Resource A (ENA-A) is alkaline water that is composed of refined edible cuttlefish bone and two different species of seaweed, Phymatolithon calcareum and Lithothamnion corallioides. In the present study, ENA-A was investigated as an antioxidant to protect against CCl(4)-induced oxidative stress and hepatotoxicity in rats. Liver injury was induced by either subacute or chronic CCl(4) administration, and the rats had free access to tap water mixed with 0% (control group) or 10% (v/v) ENA-A for 5 or 8?weeks. The results of histological examination and measurement of antioxidant activity showed that the reactive oxygen species production, lipid peroxidation, induction of CYP2E1 were decreased and the antioxidant activity, including glutathione and catalase production, was increased in the ENA-A groups as compared with the control group. On 2-DE gel analysis of the proteomes, 13 differentially expressed proteins were obtained in the ENA-A groups as compared with the control group. Antioxidant proteins, including glutathione S-transferase, kelch-like ECH-associated protein 1, and peroxiredoxin 1, were increased with hepatocyte nuclear factor 3-beta and serum albumin precursor, and kininogen precursor decreased more in the ENA-A groups than compared to the control group. In conclusion, our results suggest that ENA-A does indeed have some protective capabilities against CCl(4)-induced liver injury through its antioxidant function.     

L-tryptophan administration promotes the reversion of pre-established chronic liver injury in rats treated with carbon tetrachloride

We examined the effect of L-tryptophan (Trp) administration on the reversion of CCl(4)-induced chronic liver injury after hepatotoxicant withdrawal in rats. When rats treated with CCl(4) twice a week for 6 weeks were released from CCl(4) treatment for 2 weeks, there was an incomplete reversion of liver injury. The reversion was enhanced by 2 weeks of daily intraperitoneal administration of Trp (50 mg/kg body weight), starting just after CCl(4) withdrawal. There were increases in the levels of thiobarbituric acid reactive substances, an index of lipid peroxidation, Ca(2+), triglycerides, and Trp, and decreases in tryptophan 2,3-dioxygenase activity and serum triglyceride concentrations in the liver of rats treated with CCl(4) for 6 weeks. Serum albumin concentrations and in vitro hepatic protein synthesis activity did not change in the CCl(4)-treated rats. The changes in the CCl(4)-treated rats were partially attenuated 2 weeks after CCl(4) withdrawal. The attenuation was enhanced by 2 weeks of daily Trp administration. The increases in hepatic thiobarbituric acid reactive substances and triglycerides and the decreases in hepatic tryptophan 2,3-dioxygenase activity and serum triglyceride concentrations observed 2 weeks after CCl(4) withdrawal were almost completely attenuated by Trp administration. In vitro hepatic protein synthesis in CCl(4)-treated and untreated rats was increased by 2 weeks of daily Trp administration. These results indicate that Trp administration promotes the reversion of pre-established chronic liver injury in rats treated with CCl(4,) and suggest that Trp exerts this effect by enhancing the improvement of several parameters of liver dysfunction associated with chronic liver injury and by stimulating hepatic protein synthesis.     

Transgene expression of human PON1 Q in mice protected the liver against CCl4-induced injury

BACKGROUND: Oxidative stress, often in association with decreased antioxidant defenses, plays a pathogenetic role in both initiation and progression of liver injuries, leading to almost all clinical and experimental conditions of chronic liver diseases. Human paraoxonase 1 (hPON1) is a liver-synthesized enzyme possessing antioxidant properties. Here, we investigate the effects of transgene-expressed hPON1 Q on alleviating lipid peroxidation and preventing liver injury in a mouse model. METHODS: The hPON1 Q gene was cloned into pcDNA3.0 plasmid and electro-transferred into mouse skeletal muscle. After CCl4 had been administrated to induce liver injury, mice were monitored for serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and malonyldialdehyde (MDA). The extent of CCl4-induced liver injury was also analyzed through histopathological observations. RESULTS: After gene delivery, hPON1 mRNA expression was detected in mouse muscle and serum PON1 activity was 1.5 times higher than that of the control counterpart. In the PON1 Q gene transferred mice, protection against CCl4-induced liver injury was reflected by significantly decreased serum ALT, AST and MDA levels compared to those in control mice (P < 0.01). Histological observations also revealed that hepatocyte necrosis, hemorrhage, vacuolar change and hydropic degeneration were apparent in control mice after CCl4 administration. In contrast, the damage was significantly prevented (P < 0.01) in the hPON1 Q transferred mice. CONCLUSIONS: Intramuscular electro-transfer of the hPON1 Q gene led to efficient expression of hPON1 in mice. Elevated levels of PON1, by virtue of its potency to alleviate oxidative stress, could protect mice from suffering CCl4-induced liver damage.     

乳酸菌源有机硒对肝损伤小鼠脾脏脂质过氧化和NK细胞活性的保护效应研究

本文通过研究乳酸茵源有机硒干预CCl4致肝损伤小鼠脾脏NK细胞活性和脂质过氧化反应的变化,探讨该有机硒在抗损伤保护过程中的效应及其机制。分别选用60只健康成年小鼠,雌雄对半,随机分成对照组(C组),有机硒组(Se组),CCl4组、CCl4-有机硒保护组(CCl4-Se组),每组15只。通过腹腔注射CCl4诱发肝损伤后,分别在第2、4周检测脾脏NK细胞活性及其组织匀浆GSH—Px、CAT、SOD活性和MDA含量变化。结果显示,在整个实验期内,C组、Se组和CCl4-Se组脾组织匀浆GSH—Px、CAT和SOD活性均高于或明显高于CCl4组,Se和CCl4-Se组与C组比较除SOD活性在第4周有明显升高外均差异不显著;CCl4组小鼠脾脏MDA含量均显著高于C组、Se组和CCl4-Se组,而CCl4-Se组与C组接近,Se组较CCl4-Se组和C组低;Se组NK细胞活性最高,第4周明显高于C组,CCl4组最低且低于或明显低于CCl4-Se、Se和C组,CCl4-Se组与C组无明显差异。结果提示,乳酸茵源有机硒能够提高正常机体抗氧化能力,在干预肝损伤过程中,可以通过改善和提高脾组织抗氧化酶活性及NK细胞活性发挥积极有效的作用。     

CCl4致小鼠肝损伤中几种免疫介质含量变化的研究

本文通过研究CCl4致小鼠肝损伤组织匀浆和血浆一些免疫介质含量的变化以探讨这些免疫介质在CCl4诱发肝损伤过程中作用机制。分别选用30只健康成年小鼠,雌雄各半,随机分成对照组和CCl4负荷组,每组15只。通过腹腔注射CCl4诱发肝损伤后,分别在第2、4、6周检测肝组织匀浆cAMP、cGMP和MDA及血浆IL-2、TNF-α水平的变化。结果显示,在整个实验期内,CCl4组肝组织匀浆cAMP水平均低于或明显低于对照组;cGMP在实验第2周后,高于或显著高于对照组;cAMP／cGMP比值呈现下降趋势,并低于或明显低于对照组;MDA含量明显高于对照组。在整个实验期内,CCl4组血浆IL-2水平下降或显著下降;TNF-α水平则均高于或显著高于对照组。结果提示,CCl4负荷诱发免疫介质cAMP、cGMP、TNF-α和IL-2发生剧烈变化,在介导肝损伤过程中可能起重要作用。     

Administration of the tris salt of alpha-tocopheryl hemisuccinate inactivates CYP2E1, enhances microsomal alpha-tocopherol levels and protects against carbon tetrachloride-induced hepatotoxicity

A series of tocopherol compounds were examined for their capacity to protect against carbon tetrachloride (CCl4)-induced hepatotoxicity in rats. Of the tocopherol compounds tested in our study, only the tris salt of d-alpha-tocopheryl hemisuccinate (TS-tris) protected against CCl4-induced hepatotoxicity. The administration of d-alpha-tocopherol (alpha-T) and the nonhydrolyzable tocopherol ether, d-alpha-tocopheryloxybutyrate tris salt (TSE-tris), failed to protect against CCl4-induced hepatotoxicity. TS-tris was the only tocopherol which significantly decreased CYP2E1 activity after 18 h. This decrease in CYP2E1 activity is likely to limit the activation of CCl4 and protect against CCl4-induced hepatotoxicity. Our results also suggest that TS-tris protection against CCl4-induced hepatotoxicity correlates with the enhanced capacity of TS-tris to deliver alpha-T and increase the antioxidant status of hepatocytes. TSE-tris did not increase cellular alpha-T levels, while administration of TS-tris produced large increases in alpha-T levels in liver homogenates as well as in liver nuclei, microsomes, mitochondria and plasma membranes. This enhanced ability to deliver tocopherol equivalents to parenchymal liver cells may be related in part to the ability of TS-tris to form liposomes in aqueous solutions. TS-tris administration protected against CCl4-induced microsomal lipid peroxide formation and inactivation of the microsomal enzyme glucose-6-phosphatase (G6Pase). Supplementation of animals with alpha-T protected against microsomal lipid peroxide formation but not against the inactivation of G6Pase. Based on our findings, we propose that high cellular levels of alpha-T protect against CCl4-induced hepatotoxicity by scavenging CCl4 radicals as well as protecting against lipid peroxidation. Our results do not support the importance of microsomal lipid peroxidation as an early event in acute CCl4-induced hepatic necrosis.     

The effects of thromboxane A2 inhibitors (OKY-046 and ONO-3708) and leukotriene inhibitors (AA-861 and LY-171883) on CCl4-induced chronic liver injury in mice

The effects of OKY-046, a selective thromboxane A2 (TxA2) synthetase inhibitor, ONO-3708, a novel TxA2 receptor antagonist, AA-861, a selective 5-lipoxygenase inhibitor and LY-171883, a peptide leukotrienes (p-LTs) receptor antagonist on the chronic liver injury were investigated in mice. The chronic liver injury was induced by the injection of carbon tetrachloride (CCl4) two times a week for twelve weeks in mice. In chronic liver injury models, significant histopathological changes in the liver and extensive elevation of glutamate transaminase (GOT and GPT) activity were observed. Administration of OKY-046, ONO-3708, AA-861 and LY-171883 for 12 weeks suppressed the elevation of serum GOT and GPT levels and histopathological changes in CCl4-induced chronic liver injury. These results suggest that TxA2 and LTs inhibitors are effective for the onset and development of chronic liver injury in mice.     

The roles played by crucial free radicals like lipid free radicals, nitric oxide, and enzymes NOS and NADPH in CCl(4)-induced acute liver injury of mice

Mice were administered a single dose of carbon tetrachloride (CCl(4)) to induce acute liver injury. We found that lactate dehydrogenase (LDH) and glutamic pyruvic transaminase (GPT) levels in serum, as well as the level of thiobarbituric acid reaction substances (TBARS) in liver homogenate increased significantly in a manner both dose dependent and time dependent after CCl(4) administration. Such results suggest that the liver is susceptible to CCl(4) treatment and that lipid peroxidation is associated with CCl(4)-induced liver injury. The spin-trapping electron paramagnetic resonance (EPR) method was used to detect nitric oxide (NO) level in liver. The chemiluminescence method was also employed to measure the NO(2)(-)/NO(3)(-) concentration in serum. The NO levels in liver tissues and NO(2)(-)/NO(3)(-) concentration in serum were found to decrease significantly both in a dose-dependent manner and in time course after CCl(4) treatment. The nitric oxide synthase (NOS) II activity in the liver, in contrast, was found to increase significantly. Our study suggests that not only should the expression of NOS be analyzed but NO organ and blood concentration must be measured in the study of diseases involving nitric oxide. L-arginine treatment had no significant effect on the liver function of CCl(4)-treated mice. It was found that NO donor sodium nitroprusside (SNP; 50 or 100 microg/kg) treatment resulted in decreases of LDH, GPT, and TBARS levels, leading to a protective effect on CCl(4)-treated mice. On the other hand, N(G)-nitro-L-arginine methyl ester (L-NAME, 100 or 300 mg/kg) treatment caused more severe liver damage. Moreover, we have found in an in vitro EPR study that SNP could scavenge lipid peroxyl radical LOO&z.rad;. The above results together suggest that NO may protect CCl(4)-induced liver injury through scavenging lipid radical, inhibiting the lipid peroxidation chain reaction. On the basis of our analysis, we put forth two explanations for the stated discrepancy between NOS II and NO production: (i) NO was used up gradually in terminating lipid peroxidation and (ii) NADPH was depleted (on the basis of correlation evidence only).